Ruxolitinib to Combat COVID-19

Sponsor
Washington University School of Medicine
Study ID
NCT04354714
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ruxolitinib — DRUG
    For patients unable to swallow pills, a ruxolitinib suspension will be administered through a nasogastric/orogastric tube
  • Peripheral blood draw — PROCEDURE
    -Screening, Day 2, Day 4, Day 8, Day 15, and Day 29

Study Details

The investigators hypothesize that JAK 1/2 inhibition with ruxolitinib, an FDA approved treatment for intermediate or high-risk myelofibrosis, could have a similar effect in patients with severe COVID-19, quelling the immune-hyperactivation, allowing for clearance of the virus and reversal of the disease manifestations.

Key Dates

Start date
Jun 30, 2020
Status verified
May 2020
Primary completion
Jul 31, 2021
Completion
Dec 31, 2021

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ruxolitinib
    -Ruxolitinib is an oral medication that will be given twice daily (BID). Dosing on Days 1 through 3 will be 5 mg BID; dosing on Days 4 through 10 will be 10 mg BID.

Primary Outcome Measure

Overall survival [ Time Frame: Through 28 days ]

Related Studies